Company profile: OMass Therapeutics
1.1 - Company Overview
Company description
- Provider of drug discovery leveraging novel mass spectrometry, offering the OdyssION platform that uses native mass spectrometry and custom chemistry to study target interactions in native ecosystems, and a small molecule pipeline targeting solute carriers, inflammasome complexes, and GPCRs for orphan and immunological diseases.
Products and services
- Mass Spectrometry-Driven Drug Discovery Programs: A novel-MS-platform-enabled discovery capability exploiting novel mass spectrometry to develop therapeutics against challenging disease targets by interrogating targets in their native ecosystems
- OdyssION™ Drug Discovery Platform: A native-MS-based platform that uses native mass spectrometry and custom chemistry to study target interactions within intact biomolecular ecosystems, aiding discovery of new medicines
- Small Molecule Therapeutics Pipeline: A small-molecule pipeline targeting solute carriers, inflammasome complexes, and GPCRs to treat orphan and immunological diseases with drug candidates.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to OMass Therapeutics
Kynos Therapeutics
HQ: United Kingdom
Website
- Description: Provider of small-molecule KMO inhibitor therapeutics for inflammation, immunity, and metabolism. Offers KNS366, a Phase I KMO inhibitor designed to reduce elevated 3-HK to prevent tissue damage and immune dysregulation during inflammation, and a portfolio targeting acute and chronic inflammatory disorders, including acute kidney injury and acute pancreatitis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kynos Therapeutics company profile →
Delinia
HQ: United States
Website
- Description: Provider of novel therapeutics for autoimmune and inflammatory diseases, with a lead program focused on a molecule that selectively potentiates and expands regulatory T cells (Tregs), the immune cells critical to maintaining self-tolerance and immune system homeostasis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Delinia company profile →
Graviton
HQ: United States
Website
- Description: Provider of novel therapeutics for autoimmune, cancer, certain genetic, fibrotic, and other serious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Graviton company profile →
TRex Bio
HQ: United States
Website
- Description: Provider of a deep biology platform that maps human tissue regulatory T cell behavior to disease using high-resolution sequencing, computational biology and translational assays to identify targets, and developer of therapeutics for cancer, fibrotic and immune-mediated diseases, including TRB-061 (TNFR2 agonist; IND-enabling, FIH 2025), TRB-031/-041 (with Eli Lilly; lead optimization) and TRB-071/-081 (target ID/validation).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TRex Bio company profile →
Accentia Biopharmaceuticals
HQ: United States
Website
- Description: Provider of immunotherapies for autoimmune-related diseases and cancer; services include hospice care providing emotional support and professional medical help to terminally ill patients, and hypnosis therapy to help patients and families deal with emotional stress, improve communication, and build stronger relationships.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Accentia Biopharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for OMass Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to OMass Therapeutics
2.2 - Growth funds investing in similar companies to OMass Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for OMass Therapeutics
4.2 - Public trading comparable groups for OMass Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →